Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.085 USD | +0.78% | +5.01% | +29.69% |
Feb. 28 | Top Midday Decliners | MT |
Feb. 28 | Top Premarket Decliners | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.27 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- Analyst opinion has improved significantly over the past four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.69% | 166M | B | ||
-3.62% | 184B | C+ | ||
-0.62% | 107B | C | ||
-2.81% | 69.44B | A | ||
+4.03% | 50.37B | B- | ||
+8.68% | 44.82B | B- | ||
+3.40% | 41.53B | B+ | ||
+3.43% | 26.84B | A- | ||
+3.66% | 26.73B | B | ||
+15.23% | 25.71B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INGN Stock
- Ratings Inogen, Inc.